Literature DB >> 16894028

Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Trisha M Wise-Draper1, Hillary V Allen, Elizabeth E Jones, Kristen B Habash, Hiroshi Matsuo, Susanne I Wells.   

Abstract

The DEK proto-oncogene has been associated with human carcinogenesis-either as a fusion with the CAN nucleoporin protein or when transcriptionally upregulated. Mechanisms of intracellular DEK functions, however, have remained relatively unexplored. We have recently demonstrated that DEK expression is induced by the high-risk human papillomavirus (HPV) E7 protein in a manner which is dependent upon retinoblastoma protein function and have implicated DEK in the inhibition of cellular senescence. Additionally, overexpression of DEK resulted in significant life span extension of primary human keratinocytes. In order to determine whether DEK expression is required for cellular proliferation and/or survival, we monitored cellular responses to the knockdown of DEK in cancer and primary cells. The results indicate that DEK expression protects both HPV-positive cancer and primary human cells from apoptotic cell death. Cell death in response to DEK depletion was accompanied by increased protein stability and transcriptional activity of the p53 tumor suppressor and consequent upregulation of known p53 target genes such as p21CIP and Bax. Consistent with a possible role for p53 in DEK-mediated cell death inhibition, the p53-negative human osteosarcoma cell line SAOS-2 was resistant to the knockdown of DEK. Finally, expression of a dominant negative p53 miniprotein inhibited DEK RNA interference-induced p53 transcriptional induction, as well as cell death, thus directly implicating p53 activation in the observed apoptotic phenotype. These findings suggest a novel role for DEK in cellular survival, involving the destabilization of p53 in a manner which is likely to contribute to human carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894028      PMCID: PMC1636856          DOI: 10.1128/MCB.00430-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  63 in total

1.  Subcellular localization of the human proto-oncogene protein DEK.

Authors:  F Kappes; K Burger; M Baack; F O Fackelmayer; C Gruss
Journal:  J Biol Chem       Date:  2001-05-01       Impact factor: 5.157

2.  The ubiquitous chromatin protein DEK alters the structure of DNA by introducing positive supercoils.

Authors:  Tanja Waldmann; Carmen Eckerich; Martina Baack; Claudia Gruss
Journal:  J Biol Chem       Date:  2002-05-07       Impact factor: 5.157

3.  Transcriptional activation by AP-2alpha is modulated by the oncogene DEK.

Authors:  Mónica Campillos; Miguel Angel García; Fernando Valdivieso; Jesús Vázquez
Journal:  Nucleic Acids Res       Date:  2003-03-01       Impact factor: 16.971

4.  Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes.

Authors:  Anita Krithivas; Masahiro Fujimuro; Magdalena Weidner; David B Young; S Diane Hayward
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  5' exon interactions within the human spliceosome establish a framework for exon junction complex structure and assembly.

Authors:  Vienna L Reichert; Hervé Le Hir; Melissa S Jurica; Melissa J Moore
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

Review 6.  Live or let die: the cell's response to p53.

Authors:  Karen H Vousden; Xin Lu
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

7.  YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter.

Authors:  Kajal V Sitwala; Kristine Adams; David M Markovitz
Journal:  Oncogene       Date:  2002-12-12       Impact factor: 9.867

8.  Overexpression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis.

Authors:  Marcelo L Larramendy; Tarja Niini; Erkki Elonen; Bálint Nagy; Juha Ollila; Mauno Vihinen; Sakari Knuutila
Journal:  Haematologica       Date:  2002-06       Impact factor: 9.941

9.  Communication of the position of exon-exon junctions to the mRNA surveillance machinery by the protein RNPS1.

Authors:  J Lykke-Andersen; M D Shu; J A Steitz
Journal:  Science       Date:  2001-09-07       Impact factor: 47.728

10.  Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek.

Authors:  Andrew D Hollenbach; Craig J McPherson; Edwin J Mientjes; Rekha Iyengar; Gerard Grosveld
Journal:  J Cell Sci       Date:  2002-08-15       Impact factor: 5.285

View more
  62 in total

1.  Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.

Authors:  Monique A Morrison; Richard J Morreale; Shailaja Akunuru; Matthew Kofron; Yi Zheng; Susanne I Wells
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 2.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

3.  MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2.

Authors:  Xin Li; Wenfeng Zhang; Liya Zhou; Donghui Yue; Xin Su
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  The nuclear DEK interactome supports multi-functionality.

Authors:  Eric A Smith; Eric F Krumpelbeck; Anil G Jegga; Malte Prell; Marie M Matrka; Ferdinand Kappes; Kenneth D Greis; Abdullah M Ali; Amom R Meetei; Susanne I Wells
Journal:  Proteins       Date:  2017-11-11

5.  The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.

Authors:  J Martinez-Useros; I Moreno; M J Fernandez-Aceñero; M Rodriguez-Remirez; A Borrero-Palacios; A Cebrian; T Gomez Del Pulgar; L Del Puerto-Nevado; W Li; A Puime-Otin; N Perez; M S Soengas; J Garcia-Foncillas
Journal:  BMC Cancer       Date:  2018-02-06       Impact factor: 4.430

Review 6.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

7.  Intercellular trafficking of the nuclear oncoprotein DEK.

Authors:  Anjan K Saha; Ferdinand Kappes; Amruta Mundade; Anja Deutzmann; David M Rosmarin; Maureen Legendre; Nicolas Chatain; Zeina Al-Obaidi; Barbara S Adams; Hidde L Ploegh; Elisa Ferrando-May; Nirit Mor-Vaknin; David M Markovitz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

8.  The fanconi anemia pathway limits human papillomavirus replication.

Authors:  Elizabeth E Hoskins; Richard J Morreale; Stephen P Werner; Jennifer M Higginbotham; Laimonis A Laimins; Paul F Lambert; Darron R Brown; Maura L Gillison; Gerard J Nuovo; David P Witte; Mi-Ok Kim; Stella M Davies; Parinda A Mehta; Melinda Butsch Kovacic; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

9.  Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells.

Authors:  Débora Sinner; Jennifer J Kordich; Jason R Spence; Robert Opoka; Scott Rankin; Suh-Chin J Lin; Diva Jonatan; Aaron M Zorn; James M Wells
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 10.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.